Updates | Events | HIGHLIGHTS
Vesalius in the News
Vesalius transfemoral DMR solution published in the EuroIntervention journal
EuroPCR 2022 was a very successful event for Vesalius. In parallel to presenting during the Innovators' Day, Vesalius solution was published in EuroIntervention, the Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions...
Vesalius is presenting its TMVr solution during the Innovators Day at EuroPCR in Paris
Dr Peter Skarsgard, Vesalius President and Chief Scientific Officer, will be presenting Vesalius TMVr solution during the Innovators Day at EuroPCR in Paris on May 19th, 2022. We believe mitral valve repair for simple or complex degenerative mitral regurgitation,...
Vesalius IP experience shared during the Access to Innovation 2022 event.
During the Access to Innovation 2022 event organized by Lifesciences BC on February 16 and 17, our Chief Operating Officer Vincent Ledoux will be speaking on a panel relating to using IP to scale companies. This conference brings together leaders from across academia,...
Vesalius celebrating 5 years of innovations
Vesalius team celebrated today 5 years of next generation engineering and advanced biomedical innovations. Advancing medicine and simplifying the treatment for Mitral Regurgitation is and will always be our priority.
Vesalius, a life sciences startup to watch according to local executive banker.
Vesalius is 1 of 4 life sciences startups to watch according to Sean Azarshahi, a VP with RBC who is very active in the life sciences space. You can find the Vancouver Tech Journal article here.
Calla TMVr System presented at TCT 2021
Calla TMVr System, our comprehensive transfemoral DMR solution, will be unveiled to the clinical community in a podium presentation in the Innovation Theatre on November 4, 3PM local time. Please come and check us out! The Transcatheter Cardiovascular Therapeutics...
Vesalius selected to pitch during the “Invest In BC” event presented by Lumira Ventures
For the fifth consecutive year, Vesalius has been selected to pitch during Invest In BC, a major and very select yearly event organized by Life Sciences British Columbia and presented by Lumira Ventures. Over two days, November 3rd and 4th, the event will bring...
The Vesalius Team Joins the 2021 Vancouver Sun Run
The Vesalius Team joins the 2021 Vancouver Sun Run Virtual Race. This year, due to the pandemic, participants were asked to choose the circuit and the time/date to run, between April 18th and 30th. The Team chose the Stanley Park route, the epitome of Vancouver...
Vesalius Cardiovascular Reaches a New and Advanced Pre-Clinical Milestone
In a first-of-its-kind study, Vesalius proves that their catheter-based anchoring to the papillary muscle is safe and durable.
Vesalius is recognized as a Top Life Science Technology by the Ready to Rocket
March 23, 2021 - Ready to Rocket, British Columbia (BC) This annual event showcases the top technology companies that are best positioned to capitalize on the largest growth trends in the technology industry. For the fourth consecutive year, Vesalius is...